News & Views | Published:

CANCER METABOLISM

Mir-roring hypoxia in EGFR-TKI tolerance

Subjects

Understanding the mechanisms by which tumour cells adapt or succumb to targeted therapies is crucial to improving cancer treatment. A study in this issue of Nature Metabolism demonstrates how microRNAs, metabolic pathways and pseudohypoxia play a major role in the drug tolerance to epidermal growth factor receptor (EGFR) inhibitors in lung adenocarcinoma.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F. & Wong, K. K. Nat. Rev. Cancer 14, 535–546 (2014).

  2. 2.

    Zhang, W. C. et al. Nat. Metab. https://doi.org/10.1038/s42255-019-0052-9 (2019).

  3. 3.

    Kluckova, K. & Tennant, D. A. Cell Tissue Res. 372, 367–378 (2018).

  4. 4.

    Ivan, M. & Kaelin, W. G. Jr. Mol. Cell 66, 772–779 (2017).

  5. 5.

    Her, Y. F. & Maher, L. J. III Int. J. Endocrinol. 2015, 296167 (2015).

  6. 6.

    Selak, M. A. et al. Cancer Cell 7, 77–85 (2005).

  7. 7.

    Calvert, A. E. et al. Cell Rep. 19, 1858–1873 (2017).

  8. 8.

    Rhiem, K. et al. Int. J. Cancer 106, 74–77 (2003).

  9. 9.

    Savage, P. et al. Cell Rep. 21, 1140–1149 (2017).

  10. 10.

    Bartel, D. P. Cell 136, 215–233 (2009).

  11. 11.

    Bertero, T. et al. PLoS One 7, e44919 (2012).

  12. 12.

    Kulshreshtha, R. et al. Mol. Cell. Biol. 27, 1859–1867 (2007).

  13. 13.

    Tsang, V. H. et al. Endocr. Relat. Cancer 21, 415–426 (2014).

Download references

Author information

Correspondence to George A. Calin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: Model for miR-147b-mediated drug tolerance to EGFR TKIs.